Context: The gut hormone neurotensin promotes fat absorption, diet-induced weight gain, and liver steatosis. Its stable precursor-hormone fragment "proneurotensin" predicts cardiometabolic disease in middle-aged populations, especially in women.
T ype 2 diabetes, strongly associated with central obesity and increased accumulation of fat in the liver, is a major risk factor for cardiovascular disease (CVD). As rates of obesity and diabetes increases world-wide, it is essential to find new ways to prevent them, especially in those subjects who run a high risk of developing diabetesrelated CVD, also called cardiometabolic disease. Although several life-style and genetic factors are known to increase the risk of diabetes development (1, 2) , much less is known about why diabetes increases the risk of CVD. If the excess risk of CVD in type 2 diabetes is mainly due to chronic hyperglycemia, one would expect reduction of glycemia to reduce the risk of CVD morbidity and mortality. Intriguingly, many such large trials have been negative (3) (4) (5) , and in recent trials of new antidiabetic agents, which did in fact reduce CVD morbidity and mortality, the positive effect could also in part be a result of these drugs' effects on other risk factors than glycemia only, such as the lowering of systolic blood pressure (6, 7) . One hypothesis is that hyperglycemia is not causally related to CVD but that some other endocrine disturbances, which precede diabetes, contributes to both diabetes and CVD development. This underlines the need of identification of novel drug targets or life style modifiable factors with causal relationship with both diabetes and CVD.
Neurotensin is a peptide of 13 amino acids, which was originally extracted from bovine hypothalamus in 1973, and subsequently identified as a neurotransmitter in the central nervous system and as a gut hormone released from specialized enteroendocrine cells of the small intestine in response to ingestion of fat (8) . The effects of neurotensin are mediated through three receptors, which are NTSR1, NTSR2, and NTSR3 (also called sortilin-1). We recently reported that neurotensin knockout mice are markedly protected from diet-induced obesity, insulin resistance, liver steatosis, and the dysmetabolic effects of neurotensin seem to be mediated both by NTSR1 and NTSR3 (8) . Interestingly, similar to neurotensin knockout mice, NTSR3 knockout mice are protected from the dysmetabolic phenotype (9) , and a genetic variation of the human NTSR3 increases the risk of coronary artery disease (10) . The evidence from animal models and human genetics for a role of an overactive neurotensin system in the development of cardiometabolic disease is further strengthened by human epidemiological findings on a stable peptide of the neurotensin precursor hormone (proneurotensin). Proneurotensin is released in equimolar amounts with the unstable mature hormone of neurotensin and proneurotensin thus reflects the concentration of neurotensin. However, due to its much greater stability ex vivo the proneurotensin assay has large advantages over the mature hormone assay, especially in stored samples. In a middle-aged Swedish population, we found that high levels of proneurotensin was associated with insulin resistance and predicted the development of obesity (8) . We also reported strong and independent associations between proneurotensin and both incidence of CVD and diabetes, however, primarily in women (11) . Recently, investigators of the US Framingham Heart Study replicated the finding of proneurotensin as an independent risk factor for CVD; however, no evidence for a gender difference was found (12) . All previous human studies on the relationship between proneurotensin and cardiometabolic outcomes have been performed in middle-aged populations. Importantly, as aging is the strongest risk factor for CVD, the great bulk of cardiovascular events occur in the older age strata of the population, highlighting the need for CVD risk assessment and preventive actions also in older segments of the population. With this background, the main aim of the current study was to test if proneurotensin predicts CVD and diabetes in a population of almost 5000 older individuals with a mean age of 69 years. We also explored the presence of a possible gender difference in the relationship between proneurotensin levels and risk of diabetes and CVD.
Methods

Study population
The cohort analyzed in the current study is described in 18, 240 individuals of the MPP were reexamined. Here, cardiovascular risk factors were reassessed and plasma with EDTA was frozen to 280 degrees for later analyses. Among these 18,240 individuals who had complete data for cardiovascular risk factors, a random sample of 5402 individuals was selected for the current study, and fasting plasma concentration of proneurotensin was measured in the previously stored plasma. The only exclusion criterion was prior participation in the other large populationbased prospective cohort study from Malmö, i.e., the Malmö Diet and Cancer study in which association between proneurotensin and cardiometabolic disease was originally demonstrated (13) . This criterion assures the current study as a completely independent replication cohort, albeit, on the average having 12 years higher age at baseline. In analysis of incident CVD, we also excluded 578 subjects who had CVD diagnosed before the baseline of the current study (i.e., before 2002-2006) leaving 4804 subjects for the analysis of incident CVD. In analysis of diabetes, 640 subjects with prevalent diabetes were excluded leaving 4511 subjects for the analysis of incident diabetes.
All subjects gave written informed consent, and the study was approved by the Regional Ethics Board in Lund, Sweden.
Clinical examination and assays
Participants underwent a clinical examination, laboratory assessment, and filled in a medical questionnaire. In the current study, data on current smoking status, use of antidiabetic and antihypertensive medication, as well as if study subjects had a physician diagnosis of diabetes before baseline were derived from the questionnaire. Weight (kg) and height (m) were measured for assessment of body mass index (BMI; kg/m 2 ). Cigarette smoking was elicited by administering a questionnaire, and current smoking was defined as any cigarette smoking with in the past year. Prevalent diabetes at the examination 2002-2006 was defined as a fasting plasma glucose level of $7.0 mmol/L or a self-reported physician's diagnosis of diabetes or use of antidiabetic medication. Blood pressure (mm Hg) was measured using an oscillometric device twice after 5 minutes of rest in the supine position. Measurements (mmol/L) of fasting total cholesterol, high-density lipoprotein (HDL) cholesterol, triglycerides, and glucose were made according to standard procedures at the Department of Clinical Chemistry at Malmö University Hospital. Low-density lipoprotein (LDL) cholesterol was estimated with the Friedewald equation. Proneurotensin was measured using a chemiluminescence-based immunoassay as described in detail previously (B.R.A.H.M.S. GmbH, Hennigsdorf/Berlin, Germany) (14) .
Follow-up and end point retrieval Subjects were followed for incident diabetes and incident CVD events, until December 31, 2010. The mean follow-up time was 5.4 6 1.6 years for analyses of incident CVD and 5.5 6 1.5 years for analyses of incident diabetes. CVD (fatal and nonfatal myocardial infarction or stroke and death due to ischemic heart disease) were identified by linking the 10-digit Swedish personal identification number with three nation registers with 100% coverage: the Swedish Hospital Discharge Register and the Swedish Cause of Death Register. These registers have been previously described and validated for classifications of outcomes (15) . Myocardial infarction was defined on the basis of International Classification of Diseases (ICD) 9 code 410 or ICD-10 code I21. Death attributable to ischemic heart disease was defined as ICD-9 codes 412 and 414, or ICD-10 codes I22, I23, or I25. Stroke was defined using codes 430, 431, 434, and 436 (ICD-9) and I60, I61, I63, and I64 (ICD-10).
New-onset diabetes cases were retrieved from six different national and regional diabetes registers: Individuals could be registered as having a diagnosis of diabetes in the nationwide Swedish National Diabetes Register (16); or in the regional Diabetes 2000 Register of the Scania region (17) of which Malmö is the largest city; or in the Swedish National Patient Register (18) , which is a principal source of data for numerous research projects that covers more than 99% of all somatic and psychiatric hospital discharges and Swedish Hospital-based outpatient care; or they could be classified as diabetes cases if they had diabetes as a cause of death in the Swedish Cause of Death Register (19) , which comprises all deaths among Swedish residents occurring in Sweden or abroad; or if they had been prescribed antidiabetic drug medication as registered in the Swedish Prescribed Drug Register (20); or if they had at least two hemoglobin (Hb) A1c recordings of $6.0% using the Swedish Mono-S standardization system, corresponding to $7.0% according to the US National Glycohemoglobin 5 Standardization Program, in the Malmö HbA 1c register (15) , which analyzed and cataloged all HbA 1c samples at the Department of Clinical Chemistry obtained in institutional and noninstitutional care in the greater Malmö area from 1988 onwards.
Statistics
The distribution of plasma proneurotensin concentration was skewed and therefore logarithmically transformed. Linear regression was performed with proneurotensin being the dependent variable and with age, gender, BMI, HDL cholesterol, LDL cholesterol, systolic blood pressure, antihypertensive therapy, current smoking, and diabetes being the explanatory variables. Proneurotensin was then related to risk of development of diabetes and CVD using crude Kaplan-Meier analysis with Breslow test for significance and multivariate adjusted Cox proportional hazards models. All Cox proportional hazards models were adjusted for age, gender, BMI, HDL cholesterol, LDL cholesterol, systolic blood pressure, antihypertensive therapy, current smoking, and diabetes, except the model for analysis of incident diabetes, which was adjusted for fasting plasma glucose level instead of prevalent diabetes. Statistical analysis was performed using SPSS (v22.0; IBM Corp., Armonk, NY). A two-sided P , 0.05 was considered significant.
Results
At baseline, the study comprised 4804 individuals without CVD and 4511 individuals without diabetes. The mean age of the 4804 individuals was 69 years, and 69.8% were males (Table 1 ). Similar to findings in middle-aged subjects (21), age was weakly but significantly inversely related to fasting plasma proneurotensin concentration in the current population of elderly subjects, in both genders. In males, each year higher age was associated with [b (95% confidence interval)] 0.037 (0.032 to 0.042) (P , 0.001) lower values of standardized and log-transformed proneurotensin concentrations. In women, each year of higher age was associated with 0.024 (0.013 to 0.036) (P , 0.001) standard deviations (SDs) lower values of log-transformed proneurotensin. After adjusting for these differences in age, there was no association between any of the cardiovascular risk factors and the baseline characteristics listed in Table 1 in any gender (Supplemental Table 1 ).
The mean follow-up time was 5.4 6 1.6 years for analyses of incident CVD and during this time 456 incident cases of CVD occurred. In the analyses of incident diabetes, the mean follow-up time was 5.5 6 1.5 years and during this time 222 incident cases of diabetes occurred.
Individuals with above vs below median levels of proneurotensin had significantly increased risk of a first CVD event as shown by Kaplan-Meier analysis (P = 0.045), with significant association in females (P = 0.044) but not in males (P = 0.777) (Fig. 1) . After adjustment for all CVD risk factors, there was still a significant association between proneurotensin and incident CVD in the entire study population (Table 2) . Each SD increment of proneurotensin conferred a 10% increased risk and subjects above vs below the median of proneurotensin had a 27% increased risk of incident CVD with no significant interaction between proneurotensin and gender and similar effect estimates in both genders (Table 2) .
Individuals with above vs below median levels of proneurotensin did not have significantly increased risk of developing diabetes during the follow-up time in crude Kaplan-Meier analysis (P = 0.112) (Fig. 2) . Neither, after full adjustment for diabetes risk factors, including baseline level of fasting glucose, was there any significant association between proneurotensin and incident diabetes in the overall population (Table 3) . There was a significant interaction between proneurotensin and gender on the outcome of incident diabetes (P = 0.029). Gender-stratified fully adjusted analyses showed that in women each 1 SD increase of fasting proneurotensin was associated with a 28% increased risk and women with above vs below median fasting concentration of proneurotensin had an almost doubled risk of incident diabetes (Table 3 ). In contrast, among males, proneurotensin did not significantly associate with incident diabetes in the fully adjusted model (Table 3 ). Similar to the fully adjusted models, in crude Kaplan-Meier analysis proneurotensin above vs below the median was significantly associated with incidence of https://academic.oup.com/jcemdiabetes in females (P = 0.004) but not in males (P = 1.000) (Fig. 2) .
Discussion
The key findings of this study are (1) that high fasting plasma concentration of proneurotensin independently predicts the development of CVD in a population with a mean age of ;70 years, and (2) that in the same population proneurotensin predicts development of newonset diabetes in women but not in men. In contrast, in our previous study of a middle-aged population (11), we found that the independent association between proneurotensin and both diabetes and CVD was restricted to women. Thus, our findings in both middle-aged and elderly Swedes support a gender-specific effect on the association between proneurotensin and diabetes risk, whereas the female-specific association between proneurotensin and CVD was not observed in the current elderly population. Lack of a gender-specific proneurotensin effect on CVD is also supported by the recent report from the Framingham Heart Study, where proneurotensin predicted CVD with no evidence of a gender difference (12) . Estrogen has been shown to upregulate neurotensin (22) ; however, women in the current study were predominantly postmenopausal. Regarding the gender difference of proneurotensin's association with diabetes development, which was observed also in this population of elderly, it can be speculated that a higher life-time exposure of neurotensin makes this possible diabetes pathophysiological pathway more important in women than in men.
In middle-aged Swedish and US populations, there was a positive relationship between proneurotensin concentration and BMI (8, 12) and we showed that high proneurotensin predicts risk of later development of obesity (8) . Furthermore, mice genetically deficient of neurotensin had reduced intestinal fat absorption and were protected from high-fat diet induced obesity and liver steatosis (8) . Despite the prospective relationship with CVD in the entire population, and that with diabetes risk in women, we did not observe any cross-sectional association between proneurotensin and BMI in the current study of elderly subjects in either gender. The reason for this discrepancy between middle-aged and elderly populations is unclear. It can be speculated that determinants of body weight and obesity risk have partially different determinants in the elderly compared with middle-aged and that the contribution of neurotensin to obesity is smaller in the elderly, whereas it remains as a risk factor for CVD. Of note, recent studies point at several obesityindependent mechanisms linking the neurotensin system to CVD. Genetic variation of NTSR3 is associated with increased risk of coronary artery disease and myocardial infarction in humans without evidence of association with obesity (10) . In addition, manipulation of NTSR3 in rodents has shown to be of importance for vascular inflammation, atherosclerosis, plaque area, and vascular calcification (10, 23, 24) . As atherosclerosis becomes more common with age, whereas obesity is more common in middle age, it can be speculated that these proatherosclerotic NTSR3 mediated mechanisms become more important with age, which potentially may explain the association between circulating proneurotensin and CVD despite lack of association with BMI.
We acknowledge several limitations. As the participants of the MPP 2002-2006 examination were all also participants in the original MPP baseline examination in 1974-1992, they represent survivors and as such are health-selected and not entirely representative of the corresponding background population. The study is observational by design and although mechanistic studies in animals indicate a causal link between the neurotensin system and CVD, we cannot draw any conclusions on causality. However, as this is the third large-scale prospective cohort study reporting an independent relationship between high fasting proneurotensin concentration in plasma and cardiovascular events, we believe that our study should encourage interventional experiments aimed at reducing plasma proneurotensin and to study its effects on cardiovascular risk. In humans, intraduodenal infusion of triglycerides containing long chain fatty acids (C18) results in increased plasma neurotensin concentration, an effect which could be blocked by lipase inhibition with orlistat (25) . Thus, one could also speculate that long-term reduction of long-chain fatty acid exposure to intestinal neurotensin secreting cells, achieved by a low-fat diet or orlistat treatment, would reduce plasma concentration of proneurotensin (and the equimolar secreted mature hormone) in the long-term setting and thus be interesting candidate interventions for reducing the increased cardiovascular risk in subjects with high proneurotensin levels in plasma. It should, however, be underlined that, in absence of causal evidence, we do not know whether high level of neurotensin triggered by fat exposure or fat exposure per se that secondarily triggers neurotensin release may explain the link between high proneurotensin and risk of cardiometabolic disease. Furthermore, one could speculate that degree of elevation of proneurotensin after a fat load would be a more relevant and stronger predictor of cardiometabolic disease than a single fasting value. Unfortunately, we were not able to assess this in the current population and further studies are needed to address this issue.
Finally, despite the negative correlation between proneurotensin and age, there was no interaction between age and proneurotensin on the outcomes of CVD and diabetes. This implies that within the age distribution of the current study population, age does not modify the association between proneurotensin level and risk.
In conclusion, in a large elderly population, proneurotensin independently predicts development of CVD, whereas it only predicts diabetes in women. This study adds to previous independent reports from large prospective studies showing that proneurotensin independently predicts cardiovascular risk, as well as to several experimental studies implying a causal link between the neurotensin system and vascular inflammation, calcification and atherosclerosis development, which should encourage future interventional experiments.
